- Home
- IDA vs KNSA Comparison
IDA vs KNSA Comparison
Compare IDA & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IDA | KNSA |
|---|---|---|
| Founded | 1915 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 7.7B |
| IPO Year | 1998 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IDA | KNSA |
|---|---|---|
| Price | $146.20 | $94.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $154.22 | $109.43 |
| AVG Volume (30 Days) | 522.3K | ★ 925.9K |
| Earning Date | 10-29-2026 | 10-27-2026 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | 7.27 | ★ 225.00 |
| EPS | ★ 5.76 | 1.14 |
| Revenue | ★ $1,746,972,000.00 | $677,564,000.00 |
| Revenue This Year | $11.58 | $54.96 |
| Revenue Next Year | $8.99 | $24.16 |
| P/E Ratio | ★ $25.60 | $84.32 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $124.12 | $37.02 |
| 52 Week High | $154.91 | $98.48 |
Technical Indicators
Market Signals| Indicator | IDA | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 60.03 |
| Support Level | $143.39 | $72.76 |
| Resistance Level | $149.47 | $98.48 |
| Average True Range (ATR) | 2.47 | 5.49 |
| MACD | 0.58 | 0.78 |
| Stochastic Oscillator | 72.79 | 84.57 |
Price Performance
Historical ComparisonAbout IDA IDACORP Inc.
Idacorp is a holding company for Idaho Power. Idacorp is a vertically integrated utility that generates, transmits, and distributes electricity to 670,000 customers in southern Idaho and eastern Oregon. The utility owns 1.8 gigawatts of hydro generation, 400 MW of coal generation, 1.4 GW of natural gas generation, and 300 MW of energy storage.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.